Bloomberg ticker: INCY US
Market capitalization: $16,227 million
Background: Incyte Corporation, a US-based biopharmaceutical company, focuses on the discovery, development and commercialization of therapies. It operates worldwide and specializes in oncology and inflammation. Key products include Jakafi (ruxolitinib), a treatment for certain types of blood cancer, and Opzelura, a cream for dermatological conditions.
- The Profitable Growth ranking of 1 was higher compared to the 10th position of the previous period
- This is world-class performance compared to 350 major healthcare companies worldwide
- The profitability ranking of 2 was worse than the growth ranking of 1
- The profitability ranking of 2 was higher compared to the 9th ranking of the previous period
- This is world-class performance compared to comparable companies
- Growth position 1 was higher compared to the 10th position of the previous period
- This is world-class performance compared to comparable companies
INDEMNIFICATION: This content is for informational purposes only. It is not intended as investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may contain errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.
#Worldclass #benchmarking #Incyte #Corporation